Compare TEVA & ROL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | ROL |
|---|---|---|
| Founded | 1901 | 1948 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 28.6B |
| IPO Year | N/A | N/A |
| Metric | TEVA | ROL |
|---|---|---|
| Price | $30.30 | $59.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $29.78 | ★ $64.00 |
| AVG Volume (30 Days) | ★ 10.6M | 2.5M |
| Earning Date | 01-28-2026 | 10-29-2025 |
| Dividend Yield | N/A | ★ 1.22% |
| EPS Growth | N/A | ★ 9.81 |
| EPS | 0.62 | ★ 1.06 |
| Revenue | ★ $16,776,000,000.00 | $3,680,306,000.00 |
| Revenue This Year | $4.74 | $12.58 |
| Revenue Next Year | $0.48 | $9.23 |
| P/E Ratio | ★ $48.27 | $56.39 |
| Revenue Growth | 0.02 | ★ 11.17 |
| 52 Week Low | $12.47 | $45.34 |
| 52 Week High | $30.20 | $61.84 |
| Indicator | TEVA | ROL |
|---|---|---|
| Relative Strength Index (RSI) | 81.00 | 52.31 |
| Support Level | $28.00 | $57.54 |
| Resistance Level | $30.20 | $61.60 |
| Average True Range (ATR) | 0.66 | 1.05 |
| MACD | 0.16 | -0.22 |
| Stochastic Oscillator | 96.20 | 55.05 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Rollins is a global leader in route-based pest control services, with operations primarily in the United States, as well as in North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US, which boasts near national coverage, and in Canada. They also have a litany of other brands, which they use to pursue customers via alternative sales channels. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on the US and Canadian markets.